NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.
Guidelines | NSCLC Guideline Updates 2026
NSCLC Guideline Updates 2026
Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Talazoparib Plus Enzalutamide for HRR-Mutated mHSPC
2
Higher Ropeginterferon Alfa-2b Exposure Liked to JAK2 Reductions in ET
3
From Functional to True Hepatitis B Cure: Jordan Feld, MD, MPH
4
FDA Approves At-Home Subcutaneous Induction for Risankizumab in Crohn Disease
5